5/8
08:40 am
prfx
PainReform CEO Ilan Hadar Discusses Latest Developments Related to PRF-110 and its Potential to Help Tackle the Opioid Epidemic on Proactiveinvestors.com [Yahoo! Finance]
Medium
Report
PainReform CEO Ilan Hadar Discusses Latest Developments Related to PRF-110 and its Potential to Help Tackle the Opioid Epidemic on Proactiveinvestors.com [Yahoo! Finance]
5/8
08:30 am
prfx
PainReform CEO Ilan Hadar Discusses Latest Developments Related to PRF-110 and its Potential to Help Tackle the Opioid Epidemic on Proactiveinvestors.com
High
Report
PainReform CEO Ilan Hadar Discusses Latest Developments Related to PRF-110 and its Potential to Help Tackle the Opioid Epidemic on Proactiveinvestors.com
4/18
02:30 pm
prfx
PainReform Announces Closing of $4 Million Public Offering [Yahoo! Finance]
Low
Report
PainReform Announces Closing of $4 Million Public Offering [Yahoo! Finance]
4/18
02:19 pm
prfx
PainReform Announces Closing of $4 Million Public Offering
Low
Report
PainReform Announces Closing of $4 Million Public Offering
4/16
08:20 am
prfx
PainReform Announces Pricing of $4 Million Public Offering [Yahoo! Finance]
Medium
Report
PainReform Announces Pricing of $4 Million Public Offering [Yahoo! Finance]
4/16
08:00 am
prfx
PainReform Announces Pricing of $4 Million Public Offering
High
Report
PainReform Announces Pricing of $4 Million Public Offering
4/9
10:38 am
prfx
EXCLUSIVE: PainReform's Non-Opiate Post-Surgical Pain Relief Treatment Outperforms Rival Medicine Under Various Testing Conditions [Yahoo! Finance]
High
Report
EXCLUSIVE: PainReform's Non-Opiate Post-Surgical Pain Relief Treatment Outperforms Rival Medicine Under Various Testing Conditions [Yahoo! Finance]
4/9
09:00 am
prfx
PainReform’s Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions
High
Report
PainReform’s Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions
4/2
10:14 am
prfx
EXCLUSIVE: PainReform Reaches 50% Enrollment Target For Phase 3 Study For Its Lead Postoperative Pain Drug [Yahoo! Finance]
Low
Report
EXCLUSIVE: PainReform Reaches 50% Enrollment Target For Phase 3 Study For Its Lead Postoperative Pain Drug [Yahoo! Finance]
4/2
08:30 am
prfx
PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy
High
Report
PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy
3/1
08:19 am
prfx
PainReform Provides Year-End Business Update [Yahoo! Finance]
High
Report
PainReform Provides Year-End Business Update [Yahoo! Finance]
3/1
08:00 am
prfx
PainReform Provides Year-End Business Update
High
Report
PainReform Provides Year-End Business Update